Sanofi Says Its €15B Dealmaking Budget, R&D Spend Should Help Ease Looming Dupixent Patent Cliff

Why It Matters

Dupixent’s patent cliff threatens a multi‑billion‑dollar revenue stream, making Sanofi’s investment plan critical to preserving earnings and market position. Successful deals could reshape the competitive landscape in biologics and specialty drugs.

Key Takeaways

• Sanofi allocates €14‑15 bn for 2026 M&A activity
• Dupixent patent expires 2027, threatening billions in sales
• R&D budget increased to €7 bn to fuel pipeline
• Targeted acquisitions include biotech firms with late‑stage candidates
• Goal: offset revenue loss and sustain growth trajectory

Pulse Analysis

Dupixent has been a cornerstone of Sanofi’s specialty portfolio, generating over €5 billion in annual sales across atopic dermatitis, asthma and chronic rhinosinusitis. Its patent protection runs out in 2027, exposing the company to a steep revenue decline unless a robust successor is in place. The looming cliff is not unique to Sanofi; the broader pharma industry faces similar challenges as biologic patents expire, prompting a wave of strategic repositioning.

In response, Sanofi unveiled a €14‑15 billion M&A war chest for the year, a figure that places it among the most aggressive spenders in the sector. Coupled with an estimated €7 billion R&D allocation, the plan emphasizes both inorganic growth through acquisitions and organic innovation via internal pipelines. By targeting late‑stage biotech candidates, Sanofi hopes to secure assets that can quickly replace Dupixent’s earnings while diversifying therapeutic focus beyond immunology.

Investors are watching closely, as the success of these deals will determine whether Sanofi can maintain its dividend trajectory and market‑share momentum. A well‑executed acquisition slate could not only plug the anticipated revenue gap but also position the company as a leader in next‑generation biologics. Conversely, missed opportunities may accelerate competitive pressures from rivals already bolstering their own pipelines, underscoring the high stakes of Sanofi’s 2026 investment strategy.